Recent News

• 06.04.2025 - 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
• 06.04.2025 - 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format
• 06.03.2025 - Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
• 06.03.2025 - Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals
• 05.15.2025 - 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
• 05.15.2025 - 60 Degrees Pharmaceuticals Announces First Quarter 2025 Results
• 04.22.2025 - Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
• 04.22.2025 - Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey
• 04.10.2025 - Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21
• 04.10.2025 - Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.09.2025 - 8-K Current report
• 04.02.2025 - EFFECT Notice of Effectiveness
• 03.31.2025 - CORRESP Correspondence